335 related articles for article (PubMed ID: 6539164)
1. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
2. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Greer SB
Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
[TBL] [Abstract][Full Text] [Related]
3. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
4. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine.
Russell KJ; Rice GC; Brown JM
Cancer Res; 1986 Jun; 46(6):2883-7. PubMed ID: 3698014
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
Kaysen J; Spriggs D; Kufe D
Cancer Res; 1986 Sep; 46(9):4534-8. PubMed ID: 2425957
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and mechanism of action of 5-fluorodeoxycytidine.
Newman EM; Santi DV
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6419-23. PubMed ID: 6959127
[TBL] [Abstract][Full Text] [Related]
8. Five-chlorodeoxycytidine, a tumor-selective enzyme-driven radiosensitizer, effectively controls five advanced human tumors in nude mice.
Greer S; Alvarez M; Mas M; Wozniak C; Arnold D; Knapinska A; Norris C; Burk R; Aller A; Dauphinée M
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):791-806. PubMed ID: 11697326
[TBL] [Abstract][Full Text] [Related]
9. Reversal of deamination-related cytotoxicity of 5-methyl-2'-deoxycytidine by tetrahydrouridine in human leukemia cells.
Jekunen A; Vilpo JA
J Natl Cancer Inst; 1984 Nov; 73(5):1087-91. PubMed ID: 6593484
[TBL] [Abstract][Full Text] [Related]
10. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
11. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture.
Boothman DA; Briggle TV; Greer S
Mol Pharmacol; 1985 May; 27(5):584-94. PubMed ID: 2581125
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
13. Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase.
Momparler RL; Rossi M; Bouchard J; Vaccaro C; Momparler LF; Bartolucci S
Mol Pharmacol; 1984 May; 25(3):436-40. PubMed ID: 6203026
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line.
Balzarini J; De Clercq E; Ayusawa D; Seno T
Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):19-28. PubMed ID: 3990443
[TBL] [Abstract][Full Text] [Related]
15. Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
Holleran JL; Beumer JH; McCormick DL; Johnson WD; Newman EM; Doroshow JH; Kummar S; Covey JM; Davis M; Eiseman JL
Cancer Chemother Pharmacol; 2015 Oct; 76(4):803-11. PubMed ID: 26321472
[TBL] [Abstract][Full Text] [Related]
16. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting deoxycytidylate deaminase activity in some transplantable rat hepatomas.
Blocker R; Roth JS
Cancer Res; 1977 Jun; 37(6):1918-22. PubMed ID: 192466
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution, Tumor Detection, and Radiation Dosimetry of
Young CR; Adler S; Eary JF; Lindenberg ML; Jacobs PM; Collins J; Kummar S; Kurdziel KA; Choyke PL; Mena E
J Nucl Med; 2019 Apr; 60(4):492-496. PubMed ID: 30389817
[TBL] [Abstract][Full Text] [Related]
20. Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine.
Santos O; Perez LM; Briggle TV; Boothman DA; Greer SB
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):357-65. PubMed ID: 2394614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
